Clinical Trials Logo

Digestive System Diseases clinical trials

View clinical trials related to Digestive System Diseases.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04695340 Withdrawn - Clinical trials for Familial Amyloidosis

Effect of Psyllium (Plantago Ovata) on Digestive Disorders in Familial Amyloidosis

Psyllium
Start date: November 2023
Phase: N/A
Study type: Interventional

Familial amyloidosis is a rare disease that mainly affects the nerves and heart, but also more rarely the eyes and kidneys. This disease is due to a mutation in the gene encoding the synthesis of transthyretin, resulting in a modification of the translated protein. This abnormal protein and its derivatives are deposited in the form of a toxic "amyloid" substance in tissues and organs, altering their functions, particularly in the gastrointestinal tract. From a gastrointestinal perspective, different treatments can be proposed in the absence of specific recommendations for familial amyloidosis. The hygienic and dietary measures consist of avoiding tobacco, alcohol and carbonated drinks, limiting fatty meals rich in poorly digestible fibers, and splitting meals. If this fails, metoclopramide and domperidone are suggested. As a second-line erythromycin, can be used with caution because of cardiac risks and drug interactions. Polyethylene glycol-based osmotic laxatives can be used to treat constipation. Alternating diarrhea and constipation can be treated with ispaghul-based laxatives, aiming at transit regulation. Finally, refractory diarrhea can be treated with the administration of loperamide. If this fails, treatment with a somatostatin analogue may be offered. However, all these treatments can present significant side effects, therefore natural alternatives are often sought. Psyllium in particular regulates transit by normalizing stool consistency: it is effective against digestive disorders such as constipation, but it is also effective in the event of diarrhea. It allows the formation of a viscous gel by the hydrophilicity of polysaccharides macromolecules, increasing the fecal bowl which stimulates peristalsis and facilitates defecation. The WHO has recognized that Psyllium is superior to wheat bran in the treatment of irritable bowel syndrome. The main objective of the study is to assess the effect of daily Psyllium administration on digestive quality of life in familial amyloidosis patients who suffer from digestive disorders.

NCT ID: NCT04285008 Withdrawn - Colorectal Cancer Clinical Trials

Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation

RESCue
Start date: March 3, 2020
Phase: N/A
Study type: Interventional

The primary objective of this multi-center, prospective, randomized controlled trial is to evaluate the bowel cleansing after Pure-Vu use in outpatient subjects at high risk for inadequate colon preparation as compare to standard of care.

NCT ID: NCT03884400 Withdrawn - Healthy Clinical Trials

Distribution of Biospecimens From Biorepositories/Biobanks for Research Use

Start date: January 1, 2021
Phase:
Study type: Observational

This protocol seeks to assist biorepositories/biobanks in distributing their stored specimens and data to researchers that will actually utilize them to advance medicine and technology.

NCT ID: NCT03678480 Withdrawn - Clinical trials for Primary Sclerosing Cholangitis

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, active-controlled, parallel-group study of HTD1801 in adolescents.

NCT ID: NCT03493009 Withdrawn - Colorectal Cancer Clinical Trials

Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

The primary objective of this multicenter, prospective, randomized study is to evaluate the performance of Pure-Vu System in cleansing patients' colon who are indicated for a colonoscopy procedure using one of two different reduce bowel preparation regimes.in addition, the cecum intubation rate, time to cecum, total procedure time, and adverse event will be evaluated.

NCT ID: NCT03390309 Withdrawn - Clinical trials for Functional Gastrointestinal Disorders

Evaluation of A Partially Hydrolyzed in Improving FGIDs Symptoms

Start date: July 5, 2018
Phase: N/A
Study type: Interventional

Evaluation of A Partially Hydrolyzed Whey Protein Infant Formula in Improving Functional Gastrointestinal Disorders (FGIDs) Symptoms

NCT ID: NCT03097731 Withdrawn - Clinical trials for Digestive System Disease

Epidemiological Screening of IL10RA Mutation Rate in China

Yes
Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

The presentation of IBD in early childhood is uncommon and the monogenetic defects, especially IL-10 signaling pathway play a key role in very early onset inflammatory bowel disease (VEO-IBD). IL-10 or IL-10R deficiency associated VEO-IBD is considered a rare disorder. To date, there were about 60 cases were reported all over the word. But in our Chinese VEO-IBD Collaboration Group, 42 patients with biallelic mutations affecting IL10R genes were identified from 93 VEO-IBD patients, and the mutation sites are highly concentrated, including 83.9% (26/31) with p.R101W and 55% p.T179T (17/31) mutation, and the proportion of patients from Henan( A province of China) is higher. So we speculate that IL-10RA mutation may not be very rare, and the frequency of heterozygote subjects might be higher than suspected.

NCT ID: NCT03014141 Withdrawn - Clinical trials for Gastrointestinal Disorder, Functional

Effect of Oat Bran on Bowel Function and Appetite

OATGUT
Start date: June 2018
Phase: N/A
Study type: Interventional

The consumption of oat bran fiber also has a significant bulking effect in humans. However, besides fecal bulk, dietary fiber can promote gut health in other ways. Therefore, the purpose of this study is to investigate the effects of oat bran (rich in oat beta-glucan) supplementation on bowel function and appetite.

NCT ID: NCT02514057 Withdrawn - Clinical trials for Those With and Without Gastrointestinal Disorders

Gastrointestinal Symptom Questionnaire Validation

Start date: November 2020
Phase:
Study type: Observational

Assessment of a new gastrointestinal symptom questionnaire in comparison to 2 well established and validated questionnaires that do not fully fit the requirements of an investigator concerned about gastrointestinal side effects in a patient without primary gastrointestinal disease.

NCT ID: NCT01966341 Withdrawn - Clinical trials for Irritable Bowel Syndrome (IBS)

Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease

CAPP
Start date: April 2014
Phase: N/A
Study type: Interventional

This program has been created to help patients with irritable bowel syndrome manage their symptoms and increase their functioning by using cognitive therapy skills and hypnosis.